An important clinical trial NCT02364206, including the ralimetinib, has been conducting to determine the recommended dose of the p38 inhibitor in combination with temozolomide and radiotherapy during chemoradiotherapy period (phase I) in patients with newly diagnosed GBM and to estimate the 6-month progression free survival (PFS) rate of patients when administered at the recommended dose in combination with radiotherapy and concomitant temozolomide (phase II). Here, MAPK14 is linked to glioblastoma.